ALK and lung adenocarcinoma: The radiomics model, when combined with a clinicopathological model incorporating PD-L1 and HLA-I expression to predict ALK rearrangement and lymph node metastasis status to predict DFS in ALK-rearranged lung adenocarcinomas, demonstrated superior performance compared to the clinicopathological model alone.